In conclusion, FAM3C is a new hepatokine that activates HSF1-CaM-Akt pathway to ameliorate hyperglycemia of type 1 diabetic mice by suppressing hepatic gluconeogenesis in an insulin-independent manner (Figure 9). Here, FAM3C is linked to type 1 diabetes mellitus.